Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Novartis AGNYSE: NVS

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin holds steady near 32.8%

Operating margin was 32.8% in Q2 FY2026, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 30.5%, up 0.3 pp year over year. Over 3 fiscal years it widened by 12.9 pp.

Context

  • Operating margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 12 analysts of 34.3% for the fiscal year ending Dec 2026, up from 31.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
32.8%+1.5 pp QoQ
Last fiscal yearDec 2025
31.2%+3.0 pp YoY
LTMJun 2026
30.5%+0.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.1 pp+3.7 pp+3.6 pp
1 year+3.0 pp+3.1 pp+0.1 pp
3 years+12.9 pp+5.3 pp-7.6 pp
5 years+8.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
31.2%
Year-over-year change
+3.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How NVS compares with its peers on the latest reported figures

  • NVS's LTM Jun 2026 operating margin of 30.5% is the 3rd highest of the 11 companies compared; the peer median is 24.7%.
  • Its year-over-year change of +0.3 pp is the 6th highest of 11, against a peer median of +0.1 pp.
  • Over three fiscal years its change of +12.9 pp compares with a peer median of +2.6 pp.
NVS Competitors Peer median
Operating Margin for NVS and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202643.1% -2.6 pp-1.0 pp
ABBVAbbVie Inc.LTM Sep 202635.5% +20.4 pp+1.6 pp
NVSNovartis AGLTM Jun 202630.5% +0.3 pp+12.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202628.1% +7.3 pp+8.8 pp
PFEPfizer Inc.LTM Jun 202626.7% +0.6 pp-9.9 pp
JNJJohnson & JohnsonLTM Sep 202625.7% -0.4 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202623.7% +1.6 pp+14.9 pp
GSKGSK plcLTM Jun 202620.7% +4.5 pp+3.6 pp
MRKMerck & Co., Inc.LTM Jun 202616.7% -16.9 pp+5.3 pp
SNYSanofiLTM Jun 202614.8% -3.6 pp-4.5 pp
GILDGilead Sciences, Inc.LTM Jun 2026-4.9% -32.8 pp+12.9 pp
Peer median (excluding NVS) 24.7%+0.1 pp+2.6 pp

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.97B43.46B46.66B51.72B54.81B
Cost of Revenue11.74B11.58B12.47B12.83B13.69B
Gross Profit32.24B31.88B34.19B38.9B41.12B
Gross Margin73.3%73.4%73.3%75.2%75.0%
Research & Development8.64B9.17B11.37B10.02B10.74B
Selling, General & Admin12.83B12.19B12.52B12.57B13.31B
Operating Expenses22.18B23.93B24.42B24.35B24.05B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
EBITDA30.91B14.68B18.26B20.72B22.99B
EBITDA Margin70.3%33.8%39.1%40.1%41.9%
Operating Income10.06B7.95B9.77B14.54B17.07B
Operating Margin22.9%18.3%20.9%28.1%31.2%
Interest Income71M377.74M629.24M567.68M374.91M
Interest Expense905M834.62M876.12M1.04B1.19B
Other Income / Expenses14.47B(769M)(646M)(904M)(638.25M)
Income Before Tax24.53B7.18B9.12B13.64B16.44B
Pre-Tax Margin55.8%16.5%19.6%26.4%30.0%
Income Tax Expense1.63B1.13B551M1.7B2.4B
Net Income24.02B6.96B14.85B11.94B14.06B
Net Margin54.6%16.0%31.8%23.1%25.6%
EPS (Basic)10.713.197.155.927.25
EPS (Diluted)10.633.177.105.877.19
Weighted Avg Shares2.24B2.18B2.08B2.02B1.94B
Weighted Avg Shares (Diluted)2.26B2.2B2.09B2.04B1.96B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.